EACS takes steps towards a common, auditable European standard of care
HIV capsid inhibitor may offer long-term viral suppression
One in six South Africans drug resistant before starting HIV treatment
People stay on PrEP for 14 months on average in the US, study finds
Are CD4 counts still useful in the 'treat all' era?
Multiple benefits to scaling up universal test and treat in Africa
Long-acting injectable treatment maintains viral suppression
‘Molecular scissors’ successfully remove HIV genes from all tissues in infected monkeys
Integrase inhibitor treatment leads to greater weight gain
